In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming ...

AbbVie Inc. is challenging the Trump administration’s decision to select its Botox drug for a government program that slashes ...

AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.

AbbVie sues HHS over Botox Medicare pricing, challenging CMS authority under the Inflation Reduction Act and drug price negotiation rules.

The selected medications treat a range of conditions, including cancer, psoriatic arthritis, and human immunodeficiency virus type 1 infection.

Fifteen prescription medications will be the focus of federal price negotiations that could lower prices for Medicare patients.

The Centers for Medicare & Medicaid Services (CMS) announced that Botox is among 15 prescription drugs newly added to the federal Medicare price negotiation program for 2026. This expansion is part of ...

The popular type 2 diabetes drug dulaglutide (Trulicity), botulinum toxin (Botox), and drugs to treat psoriatic arthritis, prostate cancer, and breast cancer are among the 15 drugs that the Centers ...

AbbVie has filed a lawsuit against the U.S. Department of Health and Human Services (HHS), challenging a decision by the Centers for Medicare Medicaid Services (CMS) to impose Medicare price controls ...